Inverse association between coronary artery calcification and plasma pyrophosphate: systemic deficiency and local compensation

Martin Várhegyi[1,2], Dénes Juhász[3], Anna Lovrics[1], Emese Bata[1], Zsófia Demjén Nagy[1], Dániel Kovács[1], Áron Nagy[1], Bálint Szilveszter[3], Ádám Jermendy[3], Béla Merkely[3], Dávid Szüts[1], Jeremy Lagrange[5,6], Jean-Baptiste Michel[5], Magnus Bäck[5,6,7,8], Tamás Arányi[1,4], Anikó Ilona Nagy[3]*, Flora Szeri[1]*

[1]HUN-REN Research Centre for Natural Sciences, Institute of Molecular Life Sciences, Budapest, Hungary

[2] Doctoral College of Semmelweis University, Budapest, Hungary

[3] Heart and Vascular Centre, Semmelweis University, Budapest, Hungary

[4] Department of Molecular Biology, Semmelweis University, Budapest, Hungary

[5] Université de Lorraine, INSERM, DCAC, Nancy, France.

[6] CHRU Nancy, IHU Infiny, Vandoeuvre-les-Nancy, France.

[7] Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital, 17176 Stockholm, Sweden.

[8] Department of Medicine Solna, Karolinska Institutet, 17176 Stockholm, Sweden.

* F Szeri and AI Nagy contributed equally to this work.

Corresponding author: Flora Szeri

Affiliation: HUN-REN Research Centre for Natural Sciences, Institute of Molecular Life Sciences, Budapest, Hungary

Correspondence: 2. Magyar tudosok krt., Budapest, H-1117

e-mail: szeri.flora@ttk.hu

KEYWORDS

coronary artery calcification (CAC), plasma inorganic pyrophosphate (PPi), serum alkaline phosphatase, serum inorganic phosphate

ABSTRACT

Background: Plasma inorganic pyrophosphate (PPi) is a potent endogenous inhibitor of vascular calcification, but its clinical relevance in coronary artery calcification (CAC) has not yet been established.

Objectives: This study investigates the association between plasma PPi levels and coronary artery calcification, alongside potential local vascular compensatory mechanisms.

Methods: We assessed 20 standard clinical parameters, plasma PPi concentrations, and CAC scores, alongside demographic, comorbidity, and treatment data in 127 cardiovascular patients. The association between plasma PPi and CAC was evaluated using linear and logistic regression models. To investigate potential local compensatory mechanisms, PPi release was measured *ex vivo* from human coronary artery explants stratified by calcification status.

Results: Plasma PPi levels inversely associate with left circumflex artery (LCx) calcification, particularly among patients with established CAC, supporting a localized and condition-specific contribution of circulatory PPi to vascular calcification. PPi also correlate with known modulators such as serum phosphate and alkaline phosphatase activity, and novel associations with body mass index (BMI) and self-reported vitamin D intake are identified. *Ex vivo* analyses reveal significantly elevated PPi release from calcified and atherosclerotic coronary arteries compared to healthy vessels, suggesting a compensatory response to vascular mineral stress, a finding further supported by phosphate-induced calcification experiments in A7r5 vascular smooth muscle cell cultures.

Conclusions: These findings provide the first clinical evidence linking plasma PPi with CAC and support a dual mechanism: systemic PPi deficiency may promote vascular calcification, while ongoing mineralization stress may trigger an increase in local PPi generation limiting further progression. These insights position PPi as a potentially valuable therapeutic target for the prevention and treatment of CAC.

ABBREVIATIONS

ABCC6   ATP binding cassette subfamily C member 6

AICc   corrected Akaike information criterion

ALP	alkaline phosphatase
ANK(H)	progressive ankylosis protein (homologue)
CAD	coronary artery disease
CAC	coronary artery calcium or coronary artery calcification
CCTA	cardiac computed tomography angiography
CT	computed tomography
DM	diabetes mellitus
eGFR	estimated glomerular filtration rate
ENPP1	ectonucleotide pyrophosphatase/phosphodiesterase 1
HbA1c	hemoglobin A1c
HT	hypertension
LDL-C	low density lipoprotein cholesterol
HDL-C	high density lipoprotein cholesterol
LAD	left anterior descending artery
LCx	left circumflex artery
LCx CAC	Agatston score of the left circumflex artery
LM	left main coronary artery
Lp(a)	lipoprotein(a)
MLR	multiple linear regression
Pi	serum inorganic phosphate
PPi	plasma inorganic pyrophosphate
PXE	pseudoxanthoma elasticum
RCA	right coronary artery
sumCAC	Agatston score of the total coronary artery calcium
TAI	thrombocyte aggregation inhibitor
TG	triglycerides
TNAP	tissue non-specific alkaline phosphatase
VSMC	vascular smooth muscle cell

INTRODUCTION

Coronary artery calcification (CAC) is strongly associated with coronary artery disease (CAD) and cardiovascular disease, a leading cause of death worldwide (1-4). In

asymptomatic patients, the presence and extent of CAC reflect the cumulative burden of subclinical atherosclerosis and provide valuable prognostic information beyond traditional risk factors (5-7). As an independent predictor of adverse cardiovascular outcomes including myocardial infarction, stroke and cardiovascular mortality (8, 9), CAC becomes increasingly prevalent with advancing age. The two distinct types of CAC are not distinguishable with cardiac computed tomography angiography (CCTA): the frequent atherosclerotic calcification primarily affects the tunica intima, while the less prevalent medial calcification (also known as Monckeberg's arteriosclerosis) takes place in the tunica media. The main mechanism of intimal CAC includes endothelial dysfunction, lipid accumulation and inflammation, plaque formation, vascular smooth muscle cell (VSMCs) activation, osteogenic differentiation, and calcium deposition (10). However, in medial CAC, the key mechanism is the osteochondrogenic transdifferentiation of VSMCs, with subsequent matrix vesicle release and extracellular matrix remodeling, arterial wall stiffening leading to hypertension, cardiac hypertrophy, and heart failure (11). The etiology of CAC is multifactorial (12), encompassing genetic predisposition, environmental exposures, and modifiable lifestyle factors. Despite ongoing research, the underlying molecular mechanisms remain incompletely elucidated, and targeted therapeutic strategies are currently lacking. The established CAC risk factors include aging, male sex or post menopause, dyslipidemia, hypertension, obesity and smoking (3, 13). Additionally, in hemodialysis and advanced chronic kidney disease, especially the medial type of CAC is significantly increased, accompanied by hyperphosphatemia, elevated parathyroid hormone (PTH) and increased fibroblast growth factor-23 (FGF-23) levels (14). Moreover, metabolic syndrome and diabetes accelerate medial type CAC (15, 16) through the combined effects of endothelial dysfunction, inflammation, altered calcium-phosphate balance, hyperglycemia, and oxidative stress (17, 18). Sedentary lifestyle and western-type diet further contribute to CAC progression. Finally, ethnicity (19), and genetic predisposition to elevated lipoprotein(a) [Lp(a)] levels, along with insufficient levels of calcification inhibitors, such as matrix Gla protein (MGP) (20) and deficiency of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) (21-23) may drive or contribute to the acceleration of CAC.

ENPP1 is the only extracellular enzyme that can generate inorganic pyrophosphate (PPi) (24), a key endogenous inhibitor of vascular calcification. The predominantly hepatocyte-specific transporter ABCC6 and the more ubiquitously expressed ANKH protein mediate the release of ATP into the circulation (25, 26) supplying the substrate for ENPP1 to generate PPi. Tissue-nonspecific alkaline phosphatase (TNAP), through its associated alkaline phosphatase (ALP) activity, subsequently degrades PPi into inorganic phosphate (Pi), thereby removing a critical endogenous inhibitor of calcification (27). Consequently, hereditary deficiencies in factors responsible for PPi generation result in absent or reduced systemic PPi levels and are causative of rare calcification disorders; Generalized Arterial Calcification of Infancy (GACI) (22), Pseudoxanthoma Elasticum (PXE) (25), and Craniometaphyseal Dysplasia (CMD) (28). Fully or incompletely penetrant loss of function ABCC6 variants cause PXE (29), in which cardiovascular manifestations, including CAD, have been reported (30, 31). Furthermore, the most frequent ABCC6 missense variant has been associated with an increased CAD prevalence (32). Importantly, PPi levels are significantly decreased in end-stage chronic kidney disease patients and in hemodialysis, coinciding with progressed medial calcification, and increased ALP activity (33, 34). A recent study directly linked PPi deficiency to diabetes in animal models, demonstrating that elevated glucose levels lead to downregulation of ENPP1 and upregulation of ALP, thereby increasing the propensity for vascular calcification (35).

Based on the above accumulating evidence, we hypothesize that circulating PPi levels may play a role in the pathogenesis of CAC and CAD. To our knowledge, this is the first study to investigate clinical and biochemical correlates of plasma PPi levels in this relation. In addition, we examine the possibility of a local, PPi-mediated compensatory mechanism using *ex vivo* human coronary artery explants and *in vitro* calcification assays. If plasma PPi levels are found to be associated with CAC, therapies aimed at increasing PPi levels, currently under investigation in clinical trials for PXE, may have the potential to slow CAC progression and reduce the risk of related conditions.

METHODS
Patient population

Patients referred for clinically indicated CCTA were prospectively enrolled in this study. Patients were contacted before enrolment to confirm their willingness to participate and to ensure adherence to the pre-procedural requirements crucial for proper determination of plasma PPi level (see requirements at blood sampling). Patients with conditions that may interfere with either CAC quantification or plasma PPi measurements were not enrolled in the study. Specifically, individuals with mineral metabolism disorders or severe renal impairment (defined as an estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m², by the CKD-EPI creatinine equation) in previous medical history were not contacted, due to the known association between end-stage kidney disease and increased vascular calcification. Additionally, patients with coronary artery stents, which can impair the accuracy of CAC scoring, and individuals receiving bisphosphonate or vitamin K antagonist therapy, which may alter PPi metabolism and ectopic mineralization, were not enrolled. Hypertension (HT) and diabetes mellitus (DM) were highly prevalent in our patient population; therefore, we could not include these as exclusion criteria. Demographic and clinical data were obtained at the time of enrolment using a structured questionnaire, including comorbidities (e.g., DM and HT) and treatments (e.g., statins and anticoagulants). Electronic medical records were reviewed to supplement or verify the information provided. The study was approved by the Scientific and Research Ethics Committee of the Hungarian National Medical Scientific Council (BMEÜ/3473-1/2022/EKU). The study protocol complied with the declaration of Helsinki. All participants provided written informed consent for CT imaging, blood sampling, and statistical data analysis.

Blood sampling
Patients were asked to strictly adhere to the pre-procedural requirements, including a minimum of 8 hours of fasting, abstinence from beverages other than tap water, and avoidance of strenuous physical activity prior to the examination. Venous blood samples were collected prior to the CCTA procedure using a 21-gauge (or larger) intravenous cannula, with care taken to minimize tissue trauma. If the initial venipuncture attempt was unsuccessful, a second attempt was made in the contralateral arm. Patients requiring more than two attempts were excluded from the study to avoid confounding effects from tissue injury. For plasma inorganic

pyrophosphate (PPi) measurement, blood was always collected into the second vacuum tube containing K$_3$EDTA and gently inverted four times immediately after blood collection. To minimize pre-analytical variability, samples designated for PPi analysis were handled at room temperature with particular care, as cold or mechanical stress can significantly alter PPi concentrations. All samples were transferred to the preparative laboratory within 30 minutes of collection.

Sample preparation and determination of routine clinical laboratory parameters

Whole blood, EDTA-anticoagulated plasma, and serum samples were used for routine clinical laboratory analyses. Whole blood was used for hematology (e.g., blood count), EDTA plasma for HbA1c (hemoglobin A1c) measurement, and serum—either from plain or gel-separation tubes—for blood chemistry and lipoprotein(a) [Lp(a)] analysis. Plasma and serum fractions were separated according to standard protocols, and all parameters were measured following the routine procedures of the Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.

Sample preparation for inorganic pyrophosphate determination

The plasma fraction from the blood harvested to a vacuum tube containing K$_3$EDTA (36) was isolated via two consecutive repeated centrifugations (1000g for 5 minutes at room temperature) and transferred into platelet separation tubes (Vivaspin Filtrate, 300kDa, 13279-E, Sartorius, Göttingen, Germany). The platelet-free plasma was obtained by further centrifugation at 2000 g for 30 minutes at room temperature and stored at -80˚C until PPi measurement (conducted within 3-months).

Inorganic pyrophosphate determination

The PPi content of the plasma was determined enzymatically, using the ATPS bioluminescent method, with slight modifications. First, PPi was converted into ATP in an assay containing 80 μM MgCl2, 50 mM HEPES pH 7.4, 32 mU/ml ATP Sulfurylase (M1017B, New England Biolabs, Ipswich, MA, USA) and 16 μM adenosine 5´-phosphosulfate (A5508, Sigma-Aldrich, Saint Louis, MO, USA). Samples were incubated at 37°C for 30 minutes, followed by enzyme inactivation at 90°C for 10 minutes. In the next step, ATP levels were evaluated utilizing the BacTiterGlo

(Promega, Madison, WI, USA) bioluminescent assay, prepared according to the manufacturer's instructions, and analyzed in a multimode plate reader (PerkinElmer). Plasma PPi concentrations were calculated using calibration standards and correction for initial plasma ATP concentrations (25). Plasma samples with ATP concentrations exceeding 0.6μM were excluded from PPi analysis, based on a predefined quality control threshold to ensure appropriate blood collection and pre-analytical processing.

Cardiac CT angiography (CCTA) acquisition and calcium scoring
CCTA scans were conducted using either a dedicated cardiac CT system (CardioGraphe, GE Healthcare, Chicago, IL, USA) or a third-generation dual-source CT scanner (SOMATOM Force, Siemens Healthineers, Forchheim, Germany), employing a prospectively ECG-triggered axial scan mode. All examinations were performed at a tube voltage of 120 kVp, with tube current modulation based on individual patient body size. For CAC assessment, non-contrast-enhanced scans were obtained with 2 mm slice thickness, applying iterative reconstruction techniques. CAC scoring was carried out offline using the Agatston method (37, 38) on a dedicated analysis workstation equipped with commercially available software (HeartBeat CS, Philips Healthcare, Cleveland, OH, USA). A single trained investigator evaluated all scans, identifying coronary calcifications on axial images. Total coronary artery calcium (sumCAC) score was calculated as the sum of Agatston scores across the major coronary arteries; left main coronary artery (LM), left anterior descending artery (LAD), left circumflex artery (LCx) and right coronary artery (RCA).

PPi determination in conditioned media from coronary artery explants
Human coronary artery walls, including healthy and diseased arteries at different stages of atherosclerotic diseases, were collected from the Inserm human CV biobank (BB-0033-00029, U 1148, X. Bichat Hospital, Paris), included in the European network BBMRI-ERIC, in accordance with the French regular and ethical rules (BioMedicine Agency convention DC2018-3141) and the principles of the declaration of Helsinki. Approval was obtained from the French Biomedical Agency (ABM, PFS09-007 & PFS17-002) and the Institutional Ethical Review board (SC09-09-66). Tissues were obtained from deceased organ donors for kidney and/or hepatic transplantation in the

absence of therapeutic uses for the heart. When collected, healthy coronary arteries were macroscopically analyzed by a trained vascular surgeon to ensure that these samples were not pathological (absence of fatty streak or atherosclerosis plaques after longitudinal opening). Explants were stratified into three categories: arteries with calcified atherosclerotic lesions, arteries with atherosclerotic lesions, or control arteries without atherosclerotic lesions. Conditioned media were prepared from small pieces (about 2 mm^3) of tissue, weighed, and incubated for 24 h in serum-free RPMI culture medium containing 1% L-glutamine, 1% penicillin, streptomycin, and amphotericin at 37°C (5% CO_2). For standardization, the volume of medium was adjusted to sample wet weight (6 mL per gram of tissue). Conditioned media were collected, centrifuged (14000 g for 15 min at 4°C), and stored at 80°C until PPi quantification. PPi concentrations were measured as described above, with a modification involving a fivefold increase in sample volume to account for the low PPi concentrations in the samples.

In vitro calcification assay using A7r5 vascular smooth muscle cells

A7r5 rat VSMCs, obtained from ATCC, were used for *in vitro* calcification studies. Cells were maintained according to the manufacturer's protocol in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 mg/L penicillin-streptomycin. For the calcification assay, 5×10^4 A7r5 cells were seeded into 12-well plates and allowed to adhere and grow for 24 hours. The assay was conducted as previously described (39). Briefly, calcification was initiated by replacing the medium with either phosphate-supplemented (3 mM Pi) or standard control medium (1 mM Pi). Media were refreshed at 72 and 120 hours, and cells along with conditioned media were harvested at 168 hours for analysis. Conditioned media collected at 72, 120, and 168 hours were used for PPi quantification. Cell viability and metabolic activity were assessed at 168 hours using the PrestoBlue (Invitrogen) assay according to the manufacturer's instructions. For long-term calcification assessment, cells were cultured for 21 days with medium changes every three days. Calcification was confirmed on day 21 by Alizarin Red staining. PPi concentrations in the culture media were determined as previously described (40).

Data processing, statistical and regression analysis

A total of 150 patients were enrolled. Exclusions included three patients with eGFR <30 mL/min/1.73 m², one patient with multiple liver enzyme outliers, one with a plasma PPi outlier suggestive of preanalytical error, and fifteen with plasma ATP concentrations exceeding quality control thresholds. Three patients with missing data were also excluded. Non-numeric values for Lp(a) ("<0.1") and eGFR (">90") were replaced with random values within physiologically plausible bounds. Binary variables were coded as 0 or 1, with 0 indicating absence (or male sex) and 1 indicating presence (or female sex).

Continuous variables were evaluated for normality via the Shapiro-Wilk test. Parametric variables are generally expressed as mean ± SEM; nonparametric variables as median [IQR]; categorical variables as counts and percentages. Spearman correlations were calculated between variables. Student's t-test, Mann-Whitney U test, or Fisher's exact test were used as appropriate. PPi levels across ex vivo artery explants were compared using Kruskal-Wallis test. A two-way repeated measures ANOVA was performed to assess Pi treatment and incubation time on PPi levels of A7r5 conditioned media. Sidak's multiple comparisons test was used post hoc to adjust for multiple testing, mean ± SD and adjusted p value is indicated. Analyses were performed in R (v4.3.3) or GraphPad Prism 10.5.0.

Univariate, multivariate linear, binary, and ordinal logistic regressions were performed in R (glm, MASS::polr). To prevent overfitting, highly intercorrelated variables (Spearman's $\rho > 0.6$; e.g., LM, LAD, RCA CAC, cholesterol, GOT, RBC, hematocrit, creatinine) were excluded, and multicollinearity was checked (VIF < 5). Reduced multivariate models included the primary independent variable plus 11 clinically relevant covariates (sex, diabetes, hypertension, smoking, age, BMI, HbA1c, HDL, LDL, Lp(a), triglycerides). Best-fit models were selected using corrected AIC when applicable. Binary logistic regression assessed associations between PPi and CAC presence (sumCAC or LCx CAC > 0 vs. 0), while ordinal logistic regression was used to test associations with sumCAC severity (none, mild, moderate, severe). Odds ratios (ORs) and 95% CIs are reported. Details of statistical modeling and diagnostics are provided in the Supplementary Methods. A p-value < 0.05 was considered statistically significant.

RESULTS

Demographic, clinical, and laboratory characteristics of patients

After exclusions, 127 participants and 31 independent variables were included in the final analysis (see Methods and Supplementary Figure 1). Based on coronary artery calcium (CAC) scores, patients were categorized as non-calcified (sumCAC = 0; n = 30) or calcified (sumCAC > 0; n = 97) (Table 1A), the latter were further stratified into mild (sumCAC 0–100; n = 43), moderate (sumCAC 100–399; n = 23), and severe (sumCAC ≥400; n = 31) groups (Table 1B).

Age was strongly associated with CAC prevalence and severity, rising from 54 years [IQR: 51–66] in non-calcified individuals to 78 years [75–80] in the severe CAC group (p < 0.001). BMI was significantly higher among calcified patients, particularly in moderate (29.69 ± 1.03 kg/m²; p = 0.038) and severe groups (28.78 ± 0.91 kg/m²; p = 0.131) compared to non-calcified (26.86 ± 0.86 kg/m²). DM prevalence increased from 6.7% to 32.3% with rising CAC (p = 0.022), as did hypertension (from 43.3% to 80.6%) and statin use (23.3% to 67.7%).

Despite these associations, plasma PPi, phosphate levels, ALP activity, and sex distribution were similar across all groups. eGFR declined across CAC severity (p < 0.001), though values remained above the threshold for impaired kidney function. Notably, LDL-C and total cholesterol were significantly lower in severe CAC, possibly reflecting statin therapy effects. HbA1C and Lp(a) levels were increased in more severe groups, while CAC scores were significantly elevated across all arterial beds in calcified groups.

Determinants of plasma PPi; inverse association with CAC

It is largely unknown what factors determine plasma inorganic pyrophosphate (PPi) levels in healthy individuals or patient populations, especially in the context of CAC. To assess factors that predict PPi levels in our cohort, we first applied univariate linear regression analysis with all available variables. As shown in bold in Figure 1A, we revealed a significant positive association of PPi levels with serum phosphate (Pi) concentration, body mass index (BMI) and self-reported vitamin D (Vit D), while PPi levels showed a significant negative association with serum alkaline phosphatase

(ALP) activity. Of note, the association of PPi with LCx CAC and sumCAC score showed inverse trends but did not reach significance (p = 0.060, and p=0.243, respectively). The proportion of variance in PPi levels explained by each variable is shown in Figure 1B, with significant determinants highlighted in red and non-significant ones in turquoise. Notably, the LCx CAC score appears as the first non-significant determinant. The univariate plots are shown in Supplementary Figure 2, except for Pi, BMI and ALP, along with LCx CAC and sumCAC, which are shown in Figure 1C.

To identify factors that predict the normally distributed plasma PPi levels while minimizing potential statistical bias from multicollinearity and confounding, we applied multivariate linear regression (MLR) models. Consistent with previous literature, as shown in Supplementary Figure 1, we observed strong intercorrelations among the CAC scores of the four main coronary artery beds. Notably, CAS in the left circumflex artery (LCx) showed the strongest inverse trend with plasma PPi level. Given this finding, we aimed to explore the potential of LCx CAC in predicting PPi levels. Simultaneously, we were also interested in the overall burden of coronary artery calcification, represented by the sum coronary artery calcium score (sumCAC). Therefore, after excluding highly correlated variables (see Methods for details), we constructed MLR models incorporating LCx CAC or sumCAC, along with variables found significant in univariate analysis (Pi, ALP and BMI, while omitting the self-reported vitamin D). To account for potential confounders, we further included established CAC risk factors: sex, age, LDL-C, HDL-C, triglycerides (TG), Lp(a), HbA1c, diabetes (DM) and hypertension (HT) status, and smoking. In models containing either LCx CAC or sumCAC scores, Pi, ALP, and BMI remained significant determinants of plasma PPi levels (Figure 2), however, notably, LCx CAC emerged as a statistically significant predictor (Figure 2A). In contrast, the negative correlation trend between PPi and sumCAC score did not reach statistical significance (Figure 2B).

Determinants of CAC; inverse association with PPi

Predictors of CAC are well established, but the association with PPi has not been examined. To address this, we first analyzed determinants of CAC using MLR in patients with calcified arteries, excluding those with zero scores to avoid distributional

bias. In the calcifying patients LCx CAC levels negatively associate with PPi and DM (Figure 3A). Other traditional risk factors were not identified as significant contributors. As the number of calcifying individuals in our study was low compared to the independent variables considered, to avoid statistical bias by overfitting, we decreased the number of independent variables by the following approach. We generated a set of alternative models in a combinatorial manner with the maximum number of independent variables fixed at seven from the pool of the fourteen variables included in Figure 3A. As age is a strong determinant, and we were interested in association with PPi, we included these two variables into all models and shuffled the other variables in a combinatorial manner. Then, from the resulting models, balancing for fit and lowest complexity, we selected the best-fitting model (Figure 3B) based on the AICc values (Figure 3C). The best model, with the lowest AICc, included six independent variables. LCx CAC was significantly positively associated with HbA1c and age, while the positive association with hypertension did not reach significance. Conversely, LCx CAC showed significant negative associations with ALP activity, DM, and PPi levels (Figure 3B). Notably, in calcifying patients, sumCAC also exhibited a similar but nonsignificant inverse trend with PPi levels in MLR (Supplementary Figure 3). In the full cohort, including both calcifying and non-calcifying individuals, plasma PPi was not significantly associated with LCx CAC or sumCAC in binary or ordinal logistic regression analyses (Supplementary Figures 4–5).

PPi release from coronary artery explants and calcifying vascular smooth muscle cells

To extend our analysis and provide additional insight, we used human coronary artery explants with or without atherosclerotic lesions to condition media. Samples were obtained from 29 donors: calcified atherosclerotic lesions (n = 11), atherosclerotic lesions without detectable calcification (n = 10), and no atherosclerotic lesions (n = 8). Comparative analysis revealed significantly higher PPi concentrations in the media from atherosclerotic arteries, regardless of calcification status (0.4104 ± 0.1059 μM PPi p = 0.0083 for non-calcified and 0.4227 ± 0.1112 μM PPi, p = 0.0023 for calcified lesions), compared to that of healthy arteries (0.0629 ± 0.0086 μM PPi) (Figure 4A).

To corroborate this novel observation, we employed an *in vitro* model using A7r5 rat VSMCs, a widely used cell line for studying vascular calcification. Cells were exposed to phosphate-enriched medium (3mM Pi) to induce osteogenic differentiation and matrix calcification, confirmed by positive Alizarin Red staining (Figure 4B). Notably, mineral stress led to a significant, time-dependent increase in extracellular PPi levels in the culture medium of calcifying A7r5 cells (0.173 ± 0.015 μM PPi, p =0.0006; 0.213 ± 0.015 μM PPi, p = 0.0004 and 0.273 ± 0.051 μM PPi, p = 0.0394) compared to cells in standard 1 mM Pi containing medium (0.013 ± 0.012 μM PPi; 0.033 ± 0.015 μM PPi; 0.047 ± 0.012 μM PPi) incubated between the 0-3th, 3-5th and 5-7th days, respectively (Figure 4B).

DISCUSSION

Clinical relevance and challenges of plasma PPi measurement

Systemic PPi deficiency, whether due to impaired synthesis or accelerated degradation, is a recognized contributor to pathological calcification. Even in physiological states, such as healthy pregnancy, plasma PPi levels decline, potentially contributing to the increased cardiovascular risk observed in multiparous women (41). Despite PPi's known role as an endogenous inhibitor of calcification (42), clinical studies examining its involvement in vascular disease are scarce. This limitation stems primarily from the analytical challenges of quantifying PPi in plasma, requiring reliable assays and strict pre-analytical processing. Although recent assay advancements have improved PPi determination, remaining analytical constrains and the need for rigorous pre-analytical processing continues to hinder its clinical implementation. To date, no studies have directly examined the association between circulating PPi levels and CAC. Our study addresses this gap in a cardiovascular patient cohort, while also identifying clinical and biochemical determinants of plasma PPi levels.

Determinants of circulating PPi levels

Hydrolysis of PPi by tissue-nonspecific ALP is a key regulatory mechanism of PPi homeostasis. This is evidenced by elevated plasma PPi in hypophosphatasia patients, deficient in ALP activity (43), and by studies demonstrating that ALP increases plasma

PPi concentration and prevents arterial calcification in CKD rodent models (44). Furthermore, physiological concentrations of Pi inhibit ALP enzymatic activity (45), suggesting reciprocal regulation.

Our results demonstrate a strong positive association between plasma PPi and serum Pi, and a robust inverse relationship between PPi and ALP activity across all univariate and multivariate models. These findings are consistent with observations in CKD and end-stage renal disease (34, 46), extending this evidence to a cardiovascular population. Together, our data confirm that ALP activity and Pi concentration are major determinants of plasma PPi levels in this clinical setting.

In addition, we identified two novel associations. Plasma PPi levels showed a consistent positive correlation with BMI, an association not previously reported. Patient reported vitamin D intake also positively correlated with PPi levels. While experimental models link vitamin D to vascular calcification (47, 48), a direct relationship with PPi has not yet been documented in humans. However, given that vitamin D levels were not directly measured in our study, this finding warrants further investigation.

CAC is a context dependent determinant of PPi levels

In univariate analyses, the inverse relationship between plasma PPi and CAC did not reach statistical significance. However, in multivariable models adjusting for traditional cardiovascular risk factors and potential confounders, left circumflex artery calcification (LCx CAC) emerged as a significant inverse predictor of PPi levels. A similar negative trend was observed for total coronary calcium burden, though it did not attain statistical significance.

These findings suggest that the extent of coronary calcification may influence circulating PPi levels, with advancing disease stage in specific vascular territories potentially affecting systemic PPi concentrations. Age, sex, and diabetes status were not significantly associated with plasma PPi in our adjusted models, although non-significant trends were observed. Females tended to have slightly higher PPi levels, while individuals with diabetes showed lower levels. This is in line with previously published results (35, 49-51), however, the influence of these demographic and clinical variables on PPi regulation remains uncertain and requires further investigation.

Plasma PPi as a potential predictor of CAC

To evaluate the predictive value of plasma PPi for CAC, we employed linear and logistic regression models using LCx CAC and total coronary calcium burden as outcome variables. In individuals with established calcification, plasma PPi levels inversely associated with LCx CAC in linear regression models, and this association remained statistically significant after adjustment for multiple potential confounders.

However, when the analysis was extended to the full cohort, including calcifying and non-calcifying individuals, the inverse association between plasma PPi and LCx CAC lost significance. Furthermore, when sumCAC was used as the outcome, plasma PPi levels were not significantly associated with calcification in multivariate linear and logistic regression analyses.

These findings suggest that circulating PPi may reflect localized calcification, particularly in the LCx, among patients with existing calcific disease. Although PPi showed a trend toward an inverse association with total coronary calcium burden, this did not reach significance, possibly due to the limited sample size. Notably, the significant inverse association between plasma PPi and LCx CAC highlights its potential as a biomarker for disease progression in this vascular territory, where calcification is linked to silent ischemia and posterior wall myocardial infarction. Overall, our results support a biologically plausible connection between reduced systemic PPi and coronary calcification, emphasizing its compartmentalized role influenced by local vascular context.

Evidence from coronary artery explants and calcifying vascular smooth muscle cells supports a local compensatory PPi response

Ex-vivo assays in conditioned media from human coronary artery explants demonstrated significantly elevated PPi levels from both calcified and non-calcified atherosclerotic arteries compared to healthy, lesion-free vessels. These findings suggest that atherosclerotic or calcified vascular tissue may actively upregulate local PPi release. Supporting this observation, phosphate-induced calcification of A7r5 rat VSMCs also resulted in a time-dependent increase in extracellular PPi levels, independent of cell death, indicating a biologically regulated response.

This proposed mechanism—local vascular PPi release in response to calcific or atherosclerotic stress—may reflect an adaptive, compensatory response aimed at

mitigating further mineral deposition in advanced disease. Notably, this concept introduces a new layer of PPi homeostasis under pathological conditions: while systemic PPi levels decline with disease progression, local PPi production may be enhanced to offset this deficiency. Further studies are needed to validate this compensatory mechanism and to determine whether modulation of local PPi release represents a viable therapeutic strategy for preventing or slowing vascular calcification.

Clinical perspective

Oral administration of PPi has been shown to elevate plasma PPi and prevent vascular calcification in preclinical models of PXE and GACI (52). The ongoing PROPHECI phase II clinical trial (PyROphosPHate supplementation to fight ECtopIc calcification in PseudoXanthoma Elasticum) aims to evaluate the safety and efficacy of oral PPi in patients with PXE. Based on our findings, such therapeutic approaches may also be relevant for preventing or attenuating CAC in broader cardiovascular populations (53). If proven effective, oral PPi supplementation could offer a novel therapeutic approach for modulating vascular calcification and its associated complications. Additionally, strategies aimed at enhancing local PPi production within diseased vessels may enable spatially precise management of arterial calcification.

Study limitations

The relatively small sample size warrants validation in larger, independent cohorts. Circadian variability in plasma PPi levels may have introduced residual confounding despite standardized sample collection protocols. Vitamin D intake was self-reported, and serum vitamin D levels—as well as other key mineralization-related biomarkers such as MGP, FGF23, and PTH—were not measured. Although patients with overt kidney dysfunction or mineral metabolism disorders were excluded, individuals with diabetes mellitus and hypertension were included due to their high prevalence in cardiovascular population and were adjusted for in the statistical analyses.

Conclusion

This study provides the first clinical evidence linking PPi levels with CAC. We extended established associations of plasma PPi with serum phosphate levels and alkaline

phosphatase activity to cardiovascular patients and identified novel correlations with body mass index and self-reported vitamin D intake. Importantly, plasma PPi levels were inversely associated with LCx calcification suggesting a context-dependent relationship. This raises the possibility that reduced circulating PPi may play a contributory role in the pathogenesis of CAC.

Additionally, our *ex vivo* and *in vivo* findings revealed a potential compensatory mechanism: significantly higher PPi production was detected from calcified and non-calcified atherosclerotic coronary arteries compared to healthy vessels along with calcifying smooth muscle cells. These results support a novel hypothesis—that not only may systemic PPi deficiency promote vascular calcification, but diseased arteries themselves may actively release PPi that limit further mineral deposition.

If validated, this dual mechanism could reshape our understanding of vascular calcification and open new avenues for therapeutic intervention. PPi may thus represent a viable target for the prevention or treatment of CAD. Further studies are needed to confirm the causal role of reduced systemic PPi in the initiation and progression of CAD, to elucidate the proposed compensatory vascular response, and to evaluate the clinical utility of PPi-based therapies.

FUNDING

This study was funded by the National Research Development and Innovation Office of Hungary (grant FK131946 to FSz, K146732 and RRF-2.3.1-21-2022-00003 to AIN, K132695 to TA, K150493 to BSz). MB was supported by the Swedish Research Council (2023-02652), Heart-Lung Foundation (2024-0697), and Region Stockholm (RS 2023-0859). Further financial support: FWO Junior Fundamental Research Project (grant G061521N) of the FWO Research Foundation Flanders, Belgium to FSz; HUN-REN ELKH-POC-2022-023 Proof of Concept Grant to FSz; János Bolyai Research Scholarship (BO/00730/19/8) of the Hungarian Academy of Sciences to FSz and BSz; ÚNKP-22-5-SE-2 and ÚNKP-23-5 New National Excellence Program of the Ministry of Culture and Innovation to FSz and BSz, respectively. FSz, TA and MB are participants of the International Network on Ectopic Calcification (INTEC).

Acknowledgement

The graphical abstract contains illustrations provided by Servier Medical Art

Conflict of interest

FSz is co-inventor on patent applications related to the use of pyrophosphate for therapeutic applications. Application NLA2017471, entitled 'Oral Pyrophosphate For Use In Reducing Tissue Calcification', is continued as WO 2018/052290, EP 3 512 530 B1, and US 11,504,395 B2. MB reports institutional speaker and consultant fees from Amarin, Amgen, Novartis, and Fresenius Kabi not related to this work.

References

1.   Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207-74.

2.   Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429.

3.   Criqui MH, Knox JB, Denenberg JO, Forbang NI, McClelland RL, Novotny TE, et al. Coronary Artery Calcium Volume and Density: Potential Interactions and Overall Predictive Value: The Multi-Ethnic Study of Atherosclerosis. JACC Cardiovasc Imaging. 2017;10(8):845-54.

4.   Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.

5.   Wong ND. Evolution of Coronary Calcium Screening for Assessment of Atherosclerotic Cardiovascular Disease Risk and Role in Preventive Cardiology. Curr Atheroscler Rep. 2022;24(12):949-57.

6.   Lima MR, Lopes PM, Ferreira AM. Use of coronary artery calcium score and coronary CT angiography to guide cardiovascular prevention and treatment. Ther Adv Cardiovasc Dis. 2024;18:17539447241249650.

7.   Hollenberg EJ, Lin F, Blaha MJ, Budoff MJ, van den Hoogen IJ, Gianni U, et al. Relationship Between Coronary Artery Calcium and Atherosclerosis Progression Among Patients With Suspected Coronary Artery Disease. JACC Cardiovasc Imaging. 2022;15(6):1063-74.

8.   Hermann DM, Gronewold J, Lehmann N, Moebus S, Jöckel KH, Bauer M, et al. Coronary artery calcification is an independent stroke predictor in the general population. Stroke. 2013;44(4):1008-13.

9.   Detrano R, Guerci A, Carr J, Bild D, Burke G, Folsom A, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. The New England journal of medicine. 2008;358(13).

10.   Nakahara T, Dweck MR, Narula N, Pisapia D, Narula J, Strauss HW. Coronary Artery Calcification: From Mechanism to Molecular Imaging. JACC Cardiovasc Imaging. 2017;10(5):582-93.

11.   Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100(21):2168-76.

12.   Hashmi S, Shah PW, Aherrahrou Z, Aikawa E, Aherrahrou R. Beyond the Basics: Unraveling the Complexity of Coronary Artery Calcification. Cells. 2023;12(24).

13.   Lansky AJ, Ng VG, Maehara A, Weisz G, Lerman A, Mintz GS, et al. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. JACC Cardiovasc Imaging. 2012;5(3 Suppl):S62-72.

14.   Neven E, D'Haese PC. Vascular calcification in chronic renal failure: what have we learned from animal studies? Circ Res. 2011;108(2):249-64.

15.   Becker A, Leber AW, Becker C, von Ziegler F, Tittus J, Schroeder I, et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic patients with diabetes mellitus: a prospective study in 716 patients over 8 years. BMC Cardiovasc Disord. 2008;8:27.

16.   Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20(10):685-95.

17.   Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, et al. Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2017;37(2):191-204.

18.   An Y, Xu BT, Wan SR, Ma XM, Long Y, Xu Y, et al. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. Cardiovasc Diabetol. 2023;22(1):237.

19.   Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005;111(10):1313-20.

20.   Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386(6620):78-81.

21.   Kavousi M, Bos MM, Barnes HJ, Lino Cardenas CL, Wong D, Lu H, et al. Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification. Nat Genet. 2023;55(10):1651-64.

22.   Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet. 2003;34(4):379-81.

23.   Bacci S, Ludovico O, Prudente S, Zhang YY, Di Paola R, Mangiacotti D, et al. The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction. Diabetes. 2005;54(10):3021-5.

24.   Rutsch F, Vaingankar S, Johnson K, Goldfine I, Maddux B, Schauerte P, et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol. 2001;158(2):543-54.

25.   Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Varadi A, et al. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014;34(9):1985-9.

26.   Szeri F, Niaziorimi F, Donnelly S, Fariha N, Tertyshnaia M, Patel D, et al. The mineralization regulator ANKH mediates cellular efflux of ATP, not pyrophosphate. J Bone Miner Res. 2022.

27.   Whyte MP, Landt M, Ryan LM, Mulivor RA, Henthorn PS, Fedde KN, et al. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate.

Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest. 1995;95(4):1440-5.

28.   Reichenberger E, Tiziani V, Watanabe S, Park L, Ueki Y, Santanna C, et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001;68(6):1321-6.

29.   Szeri F, Miko A, Navasiolava N, Kaposi A, Verschuere S, Molnar B, et al. The pathogenic c.1171A>G (p.Arg391Gly) and c.2359G>A (p.Val787Ile) ABCC6 variants display incomplete penetrance causing pseudoxanthoma elasticum in a subset of individuals. Hum Mutat. 2022;43(12):1872-81.

30.   Harmsen IM, Visseren FLJ, Kok M, de Jong PA, Spiering W. Arterial calcification volume is associated with a higher risk of cardiovascular events in pseudoxanthoma elasticum. Atherosclerosis. 2025;400:119051.

31.   Lefthériotis G, Omarjee L, Le Saux O, Henrion D, Abraham P, Prunier F, et al. The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification. Front Genet. 2013;4:4.

32.   Köblös G, Andrikovics H, Prohászka Z, Tordai A, Váradi A, Arányi T. The R1141X Loss-of-Function Mutation of the ABCC6 Gene Is a Strong Genetic Risk Factor for Coronary Artery Disease. Genet Test Mol Biomarkers. 142010. p. 75-8.

33.   Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005;16(8):2495-500.

34.   Laurain A, Rubera I, Duranton C, Rutsch F, Nitschke Y, Ray E, et al. Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease. Front Cell Dev Biol. 2020;8:586831.

35.   Flores-Roco A, Lago BM, Villa-Bellosta R. Elevated glucose levels increase vascular calcification risk by disrupting extracellular pyrophosphate metabolism. Cardiovasc Diabetol. 2024;23(1):405.

36.   Lundkvist S, Niaziorimi F, Szeri F, Caffet M, Terry SF, Johansson G, et al. A new enzymatic assay to quantify inorganic pyrophosphate in plasma. Anal Bioanal Chem. 2023;415(3):481-92.

37.   Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827-32.

38.   Blaha MJ, Mortensen MB, Kianoush S, Tota-Maharaj R, Cainzos-Achirica M. Coronary Artery Calcium Scoring: Is It Time for a Change in Methodology? JACC Cardiovasc Imaging. 2017;10(8):923-37.

39.   Shin MY, Kwun IS. Phosphate-induced rat vascular smooth muscle cell calcification and the implication of zinc deficiency in a7r5 cell viability. Prev Nutr Food Sci. 2013;18(2):92-7.

40.   Szeri F, Niaziorimi F, Donnelly S, Orndorff J, van de Wetering K. Generation of fully functional fluorescent fusion proteins to gain insights into ABCC6 biology. FEBS Lett. 2020.

41.   Veiga-Lopez A, Sethuraman V, Navasiolava N, Makela B, Olomu I, Long R, et al. Plasma Inorganic Pyrophosphate Deficiency Links Multiparity to Cardiovascular Disease Risk. Front Cell Dev Biol. 2020;8:573727.

42.   Meyer JL. Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys. 1984;231(1):1-8.

43.   Whyte MP. Hypophosphatasia: An overview For 2017. Bone. 2017;102:15-25.

44.   Tani T, Fujiwara M, Orimo H, Shimizu A, Narisawa S, Pinkerton AB, et al. Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model. J Pathol. 2020;250(1):30-41.

45.   Coburn SP, Mahuren JD, Jain M, Zubovic Y, Wortsman J. Alkaline phosphatase (EC 3.1.3.1) in serum is inhibited by physiological concentrations of inorganic phosphate. J Clin Endocrinol Metab. 1998;83(11):3951-7.

46.   O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant. 2010;25(1):187-91.

47.   Niederhoffer N, Bobryshev YV, Lartaud-Idjouadiene I, Giummelly P, Atkinson J. Aortic calcification produced by vitamin D3 plus nicotine. J Vasc Res. 1997;34(5):386-98.

48.   Bouderlique E, Tang E, Zaworski J, Coudert A, Bazin D, Borondics F, et al. Vitamin D and Calcium Supplementation Accelerate Vascular Calcification in a Model of Pseudoxanthoma Elasticum. Int J Mol Sci. 2022;23(4).

49.   Kozák E, Bartstra JW, de Jong PA, Mali WPTM, Fülöp K, Tőkési N, et al. Plasma Level of Pyrophosphate Is Low in Pseudoxanthoma Elasticum Owing to Mutations in the ABCC6 Gene, but It Does Not Correlate with ABCC6 Genotype. J Clin Med. 2023;12(3).

50.   Bernhard E, Nitschke Y, Khursigara G, Sabbagh Y, Wang Y, Rutsch F. A Reference Range for Plasma Levels of Inorganic Pyrophosphate in Children Using the ATP Sulfurylase Method. J Clin Endocrinol Metab. 2022;107(1):109-18.

51.   Van Gils M, Depauw J, Coucke PJ, Aerts S, Verschuere S, Nollet L, et al. Inorganic Pyrophosphate Plasma Levels Are Decreased in Pseudoxanthoma Elasticum Patients and Heterozygous Carriers but Do Not Correlate with the Genotype or Phenotype. J Clin Med. 2023;12(5).

52.   Dedinszki D, Szeri F, Kozak E, Pomozi V, Tokesi N, Mezei TR, et al. Oral administration of pyrophosphate inhibits connective tissue calcification. EMBO Mol Med. 2017;9(11):1463-70.

53.   Roth L, Dogan S, Tuna BG, Aranyi T, Benitez S, Borrell-Pages M, et al. Pharmacological modulation of vascular ageing: A review from VascAgeNet. Ageing Res Rev. 2023;92:102122.

Graphical Abstract

TABLES AND FIGURES

Table 1 A

Variable	Total population n=127	Non-calcified sumCAC=0 n=30	Calcified sumCAC > 0 n=97	
Demographic data, comorbidities and treatments				
Sex	49 / 127 (38.6%)	10 / 30 (33.3%)	39 / 97 (40.2%)	p = 0.529
Age (year)	70 [56 - 76]	54 [51 - 66]	73 [63 - 78]	**p < 0.001**
BMI	28.38 ± 0.42	26.86 ± 0.86	28.85 ± 0.48	**p = 0.046**
DM	26 / 127 (20.5%)	2 / 30 (6.7%)	24 / 97 (24.7%)	**p = 0.038**
HT	82 / 127 (64.6%)	13 / 30 (43.3%)	69 / 97 (71.1%)	**p = 0.008**
Statin	54 / 127 (42.5%)	7 / 30 (23.3%)	47 / 97 (48.5%)	**p = 0.020**
Anti-coagulation	48 / 127 (37.8%)	11 / 30 (36.7%)	37 / 97 (38.1%)	p = 1.000
TAI	36 / 127 (28.3%)	6 / 30 (20.0%)	30 / 97 (30.9%)	p = 0.354
Lifestyle factors from questionnares				
Smoking	36 / 127 (28.3%)	7 / 30 (23.3%)	29 / 97 (29.9%)	p = 0.644
Vit C	57 / 127 (44.9%)	13 / 30 (43.3%)	44 / 97 (45.4%)	p = 1.000
Vit D	73 / 127 (57.5%)	16 / 30 (53.3%)	57 / 97 (58.8%)	p = 0.674
Blood count data				
WBC (G/L)	7.24 [5.99 - 8.52]	7.12 [5.74 - 8.19]	7.37 [6.13 - 8.62]	p = 0.176
RBC (T/L)	4.64 ± 0.05	4.74 ± 0.11	4.61 ± 0.05	p = 0.279
Routine laboratory data				
Hb (g/L)	141 [130 - 151]	144 [132 - 156]	141 [130 - 150]	p = 0.353
Hematocrit (L/L)	0.42 [0.39 - 0.45]	0.42 [0.39 - 0.45]	0.42 [0.39 - 0.44]	p = 0.820
HbA1C (mmol/mol)	37.76 [34.97 - 42.09]	35.58 [33.77 - 40.90]	38.32 [36.03 - 43.53]	**p = 0.045**
chol (mmol/l)	5.1 ± 0.1	5.5 ± 0.2	5.0 ± 0.1	p = 0.086
TG (mmol/L)	1.3 [0.9 - 1.5]	1.2 [0.8 - 1.6]	1.3 [0.9 - 1.5]	p = 0.973
HDL (mmol/L)	1.470 [1.280 - 1.695]	1.46 [1.28 - 1.69]	1.480 [1.280 - 1.710]	p = 0.654
LDL (mmol/L)	3.11 ± 0.08	3.38 ± 0.15	3.03 ± 0.10	p = 0.072
Creatinine (umol/L)	82 [71 - 94]	79 [66 - 88]	83 [73 - 98]	p = 0.076
eGFR (ml/min/1.73 m2)	79 [66 - 88]	95 [83 - 95]	74 [62 - 85]	**p < 0.001**
ALP (U/L)	70 [60 - 86]	72 [61 - 88]	70 [60 - 85]	p = 0.955
GOT (U/L)	24 [20 - 30]	23 [20 - 31]	24 [20 - 30]	p = 0.966
GPT (U/L)	19 [16 - 29]	20 [16 - 31]	19 [15 - 28]	p = 0.483
GGT (U/L)	27 [20 - 40]	26 [16 - 38]	27 [21 - 39]	p = 0.452
Na (mmol/L)	138 [137 - 140]	138 [137 - 139]	139 [137 - 140]	p = 0.328
K (mmol/L)	4.4 [4.2 - 4.8]	4.3 [4.2 - 4.9]	4.5 [4.2 - 4.8]	p = 0.750
Total Ca (mmol/L)	2.48 [2.43 - 2.55]	2.45 [2.39 - 2.53]	2.48 [2.44 - 2.56]	p = 0.053
Lp(a) (g/L)	0.12 [0.00 - 0.58]	0.00 [0.00 - 0.15]	0.14 [0.00 - 0.75]	**p = 0.021**
Phosphate (mmol/LL)	1.10 [1.01 - 1.22]	1.08 [1.02 - 1.20]	1.10 [0.99 - 1.23]	p = 0.825
Inorganic plasma pyrophosphate data				
PPi (µM)	1.508 [1.247 - 1.750]	1.582 [1.174 - 1.737]	1.489 [1.261 - 1.761]	p = 0.914
Imaging data (A.U.)				
SumCAC	66.76 [5.32 - 385.30]	0 [0 - 0]	172.44 [48.40 - 558.35]	**p < 0.001**
LM CAC	0.00 [0.00 - 20.02]	0 [0 - 0]	0.00 [0.00 - 46.89]	**p < 0.001**
LAD CAC	30.64 [0.00 - 173.79]	0 [0 - 0]	68.19 [14.78 - 252.25]	**p < 0.001**
LCX CAC	0.00 [0.00 - 41.03]	0 [0 - 0]	4.33 [0.00 - 95.84]	**p < 0.001**
RCA CAC	0.48 [0.00 - 80.91]	0 [0 - 0]	15.74 [0.00 - 132.65]	**p < 0.001**

Table 1 B

Variable	Non-calcified sumCAC=0 n=30	Mild sumCAC 0–100 n=43		Moderate sumCAC 100–399 n=23		Severe sumCAC ≥400 n=31	
Demographic data, comorbidities and treatments							
Sex	10 / 30 (33.3%)	20 / 43 (46.5%)	p = 0.336	10 / 23 (43.5%)	p = 0.570	9 / 31 (29.0%)	p = 0.786
Age (year)	54 [51 - 66]	67 [54 - 73]	**p = 0.049**	71 [63 - 76]	**p < 0.001**	78 [75 - 80]	**p < 0.001**
BMI	26.86 ± 0.86	28.45 ± 0.67	p = 0.145	29.69 ± 1.03	**p = 0.038**	28.78 ± 0.91	p = 0.131
DM	2 / 30 (6.7%)	7 / 43 (16.3%)	p = 0.292	7 / 23 (30.4%)	**p = 0.031**	10 / 31 (32.3%)	**p = 0.022**
HT	13 / 30 (43.3%)	25 / 43 (58.1%)	p = 0.241	19 / 23 (82.6%)	**p = 0.005**	25 / 31 (80.6%)	**p = 0.004**
Statin	7 / 30 (23.3%)	13 / 43 (30.2%)	p = 0.600	13 / 23 (56.5%)	**p = 0.022**	21 / 31 (67.7%)	**p < 0.001**
Anti-coagulation	11 / 30 (36.7%)	14 / 43 (32.6%)	p = 0.804	11 / 23 (47.8%)	p = 0.574	12 / 31 (38.7%)	p = 1.000
TAI	6 / 30 (20.0%)	9 / 43 (20.9%)	p = 1.000	7 / 23 (30.4%)	p = 0.522	14 / 31 (45.2%)	p = 0.056
Lifestyle factors from questionnares							
Smoking	7 / 30 (23.3%)	7 / 43 (16.3%)	p = 0.550	9 / 23 (39.1%)	p = 0.242	13 / 31 (41.9%)	p = 0.174
Vit C	13 / 30 (43.3%)	24 / 43 (55.8%)	p = 0.346	10 / 23 (43.5%)	p = 1.000	10 / 31 (32.3%)	p = 0.434
Vit D	16 / 30 (53.3%)	28 / 43 (65.1%)	p = 0.340	13 / 23 (56.5%)	p = 1.000	16 / 31 (51.6%)	p = 1.000
Blood count data							
WBC (G/L)	7.12 [5.74 - 8.19]	7.28 [6.11 - 8.59]	p = 0.224	7.56 [6.53 - 8.77]	p = 0.203	7.06 [6.12 - 8.56]	p = 0.403
RBC (T/L)	4.74 ± 0.11	4.73 ± 0.07	p = 0.970	4.61 ± 0.10	p = 0.401	4.45 ± 0.11	p = 0.064
Routine laboratory data							
Hb (g/L)	144 [132 - 156]	145 [134 - 153]	p = 0.880	140 [132 - 143]	p = 0.440	139 [126 - 143]	p = 0.053
Hematocrit (L/L)	0.42 [0.39 - 0.45]	0.43 [0.41 - 0.45]	p = 0.521	0.41 [0.40 - 0.44]	p = 0.843	0.41 [0.37 - 0.43]	p = 0.213
HbA1C (mmol/mol)	35.58 [33.77 - 40.90]	37.44 [35.58 - 40.36]	p = 0.235	39.53 [36.04 - 45.37]	p = 0.082	39.65 [36.47 - 43.79]	**p = 0.030**
chol (mmol/l)	5.5 ± 0.2	5.4 ± 0.2	p = 0.753	5.2 ± 0.2	p = 0.385	4.4 ± 0.2	**p < 0.001**
TG (mmol/L)	1.2 [0.8 - 1.6]	1.2 [0.9 - 1.4]	p = 0.778	1.5 [1.1 - 1.9]	p = 0.318	1.1 [0.9 - 1.4]	p = 0.733
HDL (mmol/L)	1.46 [1.28 - 1.69]	1.500 [1.250 - 1.695]	p = 0.942	1.46 [1.36 - 1.56]	p = 0.733	1.53 [1.29 - 1.75]	p = 0.449
LDL (mmol/L)	3.38 ± 0.15	3.35 ± 0.16	p = 0.894	3.14 ± 0.20	p = 0.326	2.49 ± 0.12	**p < 0.001**
Creatinine (umol/L)	79 [66 - 88]	84 [73 - 98]	p = 0.116	81 [70 - 94]	p = 0.501	86 [76 - 100]	p = 0.052
eGFR (ml/min/1.73 m2)	95 [83 - 95]	78 [66 - 88]	**p = 0.002**	77 [66 - 83]	**p = 0.003**	72 [57 - 80]	**p < 0.001**
ALP (U/L)	72 [61 - 88]	77 [58 - 92]	p = 0.674	68 [58 - 85]	p = 0.802	65 [62 - 80]	p = 0.629
GOT (U/L)	23 [20 - 31]	25 [20 - 32]	p = 0.757	24 [20 - 30]	p = 1.000	24 [20 - 28]	p = 0.784
GPT (U/L)	20 [16 - 31]	22 [17 - 31]	p = 0.715	20 [16 - 32]	p = 0.978	17 [14 - 18]	**p = 0.022**
GGT (U/L)	26 [16 - 38]	28 [20 - 36]	p = 0.902	31 [22 - 67]	p = 0.187	27 [22 - 42]	p = 0.497
Na (mmol/L)	138 [137 - 139]	139 [138 - 140]	p = 0.113	138 [136 - 140]	p = 0.724	139 [138 - 140]	p = 0.460
K (mmol/L)	4.3 [4.2 - 4.9]	4.4 [4.1 - 4.6]	p = 0.464	4.7 [4.3 - 4.8]	p = 0.231	4.6 [4.2 - 4.9]	p = 0.430
Total Ca (mmol/L)	2.45 [2.39 - 2.53]	2.48 [2.43 - 2.55]	p = 0.125	2.52 [2.45 - 2.59]	**p = 0.007**	2.47 [2.44 - 2.51]	p = 0.440
Lp(a) (g/L)	0.00 [0.00 - 0.15]	0.14 [0.00 - 0.75]	**p = 0.038**	0.00 [0.00 - 0.46]	p = 0.405	0.18 [0.00 - 0.91]	**p = 0.010**
Phosphate (mmol/LL)	1.08 [1.02 - 1.20]	1.11 [0.91 - 1.22]	p = 0.991	1.07 [1.04 - 1.23]	p = 0.843	1.12 [1.02 - 1.27]	p = 0.675
Inorganic plasma pyrophosphate data							
PPi (µM)	1.582 [1.174 - 1.737]	1.459 [1.332 - 1.701]	p = 0.626	1.626 [1.373 - 1.922]	p = 0.251	1.385 [1.234 - 1.643]	p = 0.571
Imaging data (A.U.)							
SumCAC	0 [0 - 0]	37.20 [17.88 - 64.49]	**p < 0.001**	241.04 [179.80 - 352.26]	**p < 0.001**	1007.72 [707.49 - 1990.64]	**p < 0.001**
LM CAC	0 [0 - 0]	0.00 [0.00 - 0.41]	**p = 0.003**	4.29 [0.00 - 39.77]	**p < 0.001**	58.17 [6.54 - 183.98]	**p < 0.001**
LAD CAC	0 [0 - 0]	13.49 [0.00 - 31.82]	**p < 0.001**	127.69 [100.91 - 156.28]	**p < 0.001**	396.38 [270.40 - 679.79]	**p < 0.001**
LCX CAC	0 [0 - 0]	0.00 [0.00 - 0.00]	**p = 0.008**	11.92 [0.00 - 35.88]	**p < 0.001**	147.34 [71.86 - 400.34]	**p < 0.001**
RCA CAC	0 [0 - 0]	0.00 [0.00 - 12.63]	**p < 0.001**	15.74 [0.00 - 95.98]	**p < 0.001**	288.69 [89.67 - 640.79]	**p < 0.001**

Table 1

Patient characteristics and stratification.

Demographic, clinical, self-reported and routine laboratory data of patients with plasma PPi concentration and CAC (CAC) determined by the Agatston method. Based on CAC scores, patients are classified as non-calcified (sumCAC = 0; n = 30) or calcified (sumCAC > 0; n = 97) group (A). Based on sumCAC scores calcifying patents are further stratified into three groups: mild (0–100), moderate (100–399), and severe (≥400) (B). Statistical significance (p-value < 0.05) compared to values of non-calcified patients is indicated in bold. ALP, serum alkaline phosphatase activity; A.U., arbitrary unit; BMI, body mass index; chol, total cholesterol; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyl transferase; GOT, glutamic-oxaloacetic transaminase; GPT (U/L), glutamic pyruvic transaminase; Hb, hemoglobin; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cholesterol; HT, hypertension; K, potassium; LAD CAC, Agatston score of the left anterior descending artery; LCx CAC, Agatston score of the left circumflex artery; LDL-C, low density lipoprotein cholesterol; LM CAC, Agatston score of the left main coronary artery; Lp(a), lipoprotein(a); Na, sodium; Pi, serum inorganic phosphate; PPi, plasma inorganic pyrophosphate; RBC, red blood cell; RCA CAC, Agatston score of the right coronary artery; Sum CAC, Agatston score of the total coronary artery calcium; TAI, thrombocyte aggregation inhibitor; TG, triglycerides; Total Ca, total calcium; vit C, vitamin C; vit D, vitamin D; WBC, white blood cell.

Figure 1

Figure 1

Predictors of plasma PPi level in univariate linear regression.

Determinants of PPi by univariate linear regression with unselected variables (A). Proportion of variance explaining PPi levels by the variables, red indicating significant and turquoise non-significant contributors (B) Individual univariate plots depicting PPi levels in the function of ALP, Pi, BMI, LCX CAC and sumCAC (C). ALP, serum alkaline phosphatase activity; BMI, body mass index; chol, total cholesterol; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyl transferase; GOT, glutamic-oxaloacetic transaminase; GPT (U/L), glutamic pyruvic transaminase; Hb, hemoglobin; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cholesterol; HT, hypertension; K, potassium; LAD CAC, Agatston score of the left anterior descending artery; LCx CAC, Agatston score of the left circumflex artery; LDL-C, low density lipoprotein cholesterol; LM CAC, Agatston score of the left main coronary artery; Lp(a), lipoprotein(a); Na, sodium; PPi, plasma inorganic pyrophosphate; RBC, red blood cell; RCA CAC, Agatston score of the right coronary artery; Sum CAC, Agatston score of the total coronary artery calcium; TAI, thrombocyte aggregation inhibitor; TG, triglycerides; Total Ca, total calcium; vit C, vitamin C; vit D, vitamin D; WBC, white blood cell.

Figure 2

A

Figure 2

Determinants of plasma PPi level in multiple linear regression. Determinants for association of PPi with LCx CAC score and other covariates (A) or sumCAC score and additional covariates (B) in MLR. ALP, serum alkaline phosphatase activity; BMI, body mass index; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cholesterol; HT, hypertension; LCx CAC, Agatston score of the left circumflex artery; LDL-C, low density lipoprotein cholesterol; Lp(a), lipoprotein(a); Sum CAC, Agatston score of the total coronary artery calcium; TG, triglycerides.

Figure 3

A

B

C

Figure 3

Determinants of CAC in calcifying patients in multivariate linear regression.
Determinants for association with LCx CAC score with adjustment for major
confounders (A). Determinants of the best restricted model in non-calcifying patients
(B). Ranking of the best -fitting restricted models to account for decreased sample size
(C). ALP, serum alkaline phosphatase activity; BMI, body mass index; DM, diabetes
mellitus; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cholesterol; HT,
hypertension; LCx CAC, Agatston score of the left circumflex artery; LDL-C, low density
lipoprotein cholesterol; Lp(a), lipoprotein(a); PPi, plasma inorganic pyrophosphate; TG,
triglycerides.

Figure 4

Figure 4

PPi level relative to pathologies or mineral stress ex-vivo and in vitro. PPi concentration of conditioned media containing coronary artery explants obtained from 29 patients (A). Explants were stratified into arteries with calcified atherosclerotic lesions (red), arteries with non-calcified atherosclerotic lesions (blue), or control arteries with no atherosclerotic lesions (black). (B) Calcification in A7r5 rat VSMCs upon phosphate (Pi) stimulus detected by Alizarin red staining, and accumulation of PPi in the media of Pi treated and untreated A7r5 cells (B).